Notice NOT-NS-19-042 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-040 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-211 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research. Programs should be designed to enhance the breadth and depth of training in NINDS mission areas by incorporating didactic, research and career development components in the context of a defined scientific theme. Programs may support basic, clinical and/or translational research. Critical components of programs supported by this FOA include mechanisms to ensure a thorough understanding of experimental design, strong statistics and analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences. Regardless of theme, programs should provide opportunities and activities that will foster the development of quantitative literacy and the application of quantitative approaches to the trainees' research. NINDS institutional training programs are intended to be 1-2 years in duration and support training of one or more of the following groups: dissertation stage predoctoral students in their 3rd and/or 4th year of graduate school, postdoctoral fellows and fellowship-stage clinicians. (NINDS does not support first or second year graduate students under this PAR).

Notice NOT-TR-19-018 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-685 from the NIH Guide for Grants and Contracts

Notice NOT-EB-19-007 from the NIH Guide for Grants and Contracts

Notice NOT-EB-19-006 from the NIH Guide for Grants and Contracts

Notice NOT-EB-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-AA-19-014 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-044 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-037 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-19-015 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). This FOA seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this FOA provided support for up to two years (UG3 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (UH3 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases and are expected to have a substantial collaborative effort between independents laboratories. This FOA is not specific for any one or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED).

Notice NOT-EY-19-019 from the NIH Guide for Grants and Contracts

Notice NOT-HG-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-007 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-028 from the NIH Guide for Grants and Contracts

Notice NOT-HS-19-012 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-FD-19-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-19-210 from the NIH Guide for Grants and Contracts. This purpose of this FOA is to identify risk factors for dementia progression in PDD. Applicants must have access to well-characterized populations of PDD patients that have been followed longitudinally that they can continue to follow with clinical assessments and biospecimen collection until autopsy. Research should propose to identify clinical, pathological and/or biospecimen factors that predict which patients will develop cognitive impairment and/or dementia.